Project description:Interventions: CapeOX+Bev ;Capecitabine1000mg/m2 oral administration twice a day Day1-15+Oxaliplatin130mg/m2 120minute DIV+Bevacizumab5.0 mg/kg given on day 1,15 FOLFOX+Bev;Oxaliplatin85mg/m2 120minute DIV+LEVOFOLINATE200mg/m2 120minute DIV+Fluorouracil400mg/m2 rapid DIV+Fluorouracil2400mg/m2 46minute DIV+Bevacizumab DIV5.0 mg/kg Day1,15 TAS-102+Bev;TAS-102 35 mg/m2/time,oral administration twice a day Day1-5, TAS-102 oral administration twice a day Day8-12+Bevacizumab DIV5.0 mg/kg Day1,15 Primary outcome(s): Progression free survival Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2612965 | ecrin-mdr-crc

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

Project description: Not available

| S-EPMC12727869 | biostudies-literature

The role of switch maintenance therapy in urothelial cancers.

Project description: Not available

| S-EPMC9986508 | biostudies-literature

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?

Project description: Not available

| S-EPMC8616471 | biostudies-literature

Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.

Project description: Not available

| S-EPMC5519043 | biostudies-literature

Single-cell RNA-seq profiling of treatment-naïve chemo-refractory and chemo-sensitive ovarian cancer

Project description:This dataset contains single-cell RNA-seq data from treatment-naïve biopsies of nine patients diagnosed with ovarian high-grade serous carcinoma (HGSC), including four chemo-refractory and five chemo-sensitive cancers. Four of the samples (EOC204, EOC115, EOC649, EOC1127) are newly generated, while five samples have been previously published (GSE165897). The data was generated as part of the DECIDER observational trial (NCT04846933) to investigate the molecular drivers of chemo-refractory HGSC. Key findings from the study indicate that chemo-refractory HGSC is associated with reduced interferon type I (IFN-I) activity and enhanced hypoxia pathway activity, while baseline IFN-I pathway activity in chemo-naïve cancer serves as an independent prognostic factor for chemotherapy response.

2025-07-03 | GSE300897 | GEO

A mathematical model for treatment using chemo-immunotherapy.

Project description: Not available

| S-EPMC9065634 | biostudies-literature